PIKfyve blockade exposes lysosomal vulnerability in myeloma
Abstract
Recognizing these barriers, in 2024 the FDA issued 3 draft guidance documents related to clinical trial eligibility, addressing laboratory values, performance status, and washout periods/concomitant medications.2,4 Recommendations emphasized tailoring eligibility criteria to the investigational drug's mechanism of action, including patients with an Eastern Cooperative Oncology Group performance status ≤2, and liberalizing laboratory thresholds when supported by safety data.
Fields of Study & Subjects
Multiple Myeloma Research and Treatments
Lymphoma Diagnosis and Treatment
PI3K/AKT/mTOR signaling in cancer
Publication details
- Journal / source
- Blood
- Volume
- 147
- Issue
- 6
- Pages
- 605–607
- Publication date
- 5 February 2026
- Language
- EN